CDKN2A and metastatic neoplasm: While median age, gender, treatment modality, p16 status (a surrogate biomarker for HPV-positivity), as well as tumor stage at diagnosis, were not different between the two groups, MYC amplified patients showed non-significant trend toward higher rates of developing recurrent and/or metastatic disease following primary therapy, with 100% of cases among MYC amplified compared to 72.9% among the wild-type MYC counterparts (p = 0.08; Supplementary Table 1).